Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease
Author:
- 14 July 2023
- journal article
- review article
- Published by Taylor & Francis in Critical Reviews in Clinical Laboratory Sciences
- Vol. 60 (8) , 560-572
Abstract
Lipoprotein(a) is a complex lipoprotein with unique characteristics distinguishing it from all the other apolipoprotein B-containing lipoprotein particles. Its lipid composition and the presence of a single molecule of apolipoprotein B per particle, render lipoprotein(a) similar to low-density lipoproteins. However, the presence of a unique, carbohydrate-rich protein termed apolipoprotein(a), linked by a covalent bond to apolipoprotein B imparts unique characteristics to lipoprotein(a) distinguishing it from all the other lipoproteins. Apolipoprotein(a) is highly polymorphic in size ranging in molecular weight from 800 kDa. Both the size polymorphism and the concentration of lipoprotein(a) in plasma are genetically determined and unlike other lipoproteins, plasma concentration is minimally impacted by lifestyle modifications or lipid-lowering drugs. Many studies involving hundreds of thousands of individuals have provided strong evidence that elevated lipoprotein(a) is genetically determined and a causal risk factor for atherosclerotic cardiovascular disease. The concentration attained in adulthood is already present in children at around 5 years of age and therefore, those with elevated lipoprotein(a) are prematurely exposed to a high risk of cardiovascular disease. Despite the large number of guidelines and consensus statements on the management of lipoprotein(a) in atherosclerotic cardiovascular disease published in the last decade, lipoprotein(a) is still seldom measured in clinical settings. In this review, we provide an overview of the most important features that characterize lipoprotein(a), its role in cardiovascular disease, and the importance of adding the measurement of lipoprotein(a) for screening adults and youths to identify those at increased risk of atherosclerotic cardiovascular disease due to their elevated plasma concentration of lipoprotein(a).Keywords
This publication has 95 references indexed in Scilit:
- Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American childrenHaematologica, 2013
- Lipoprotein (a) Levels in Childhood Arterial Ischemic StrokeClinical and Applied Thrombosis/Hemostasis, 2009
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk FactorsCirculation, 2009
- Inhibition of Plasminogen Activation by Lipoprotein(a)Journal of Biological Chemistry, 2003
- Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS)European Journal of Clinical Investigation, 1994
- Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activationBiochemistry, 1993
- Identification of 34 Apolipoprotein(a) Isoforms: Differential Expression of Apolipoprotein(a) Alleles between American Blacks and WhitesBiochemical and Biophysical Research Communications, 1993
- Predictive value of apolipoproteins in a prospective survey of coronary artery disease in menThe American Journal of Cardiology, 1992
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987